Article
First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.
Thoracic cancer - 1 Mar 2022
Ito Noriaki, Masuda Takeshi, Ooka Ikuko, Hosoya Takatsune, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Nakashima Taku, Miyamoto Shintaro, Iwamoto Hiroshi, Fujitaka Kazunori, Hamada Hironobu, Hattori Noboru
Abstract excerpt
Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. However, there have been no reports on the efficacy of osimertinib in patients with EGFR G719S and de novo T790M mutations. Here, we present the case of a 71-year-old woman who received first-line osimertinib for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.